Rotgrün-Blindheit bei einem heterogametischen Schein-Mädchen, zugleich ein Beitrag zur Genetik der heterogametischen Pseudofemininität

1957 ◽  
Vol 6 (2) ◽  
pp. 231-246 ◽  
Author(s):  
W. Lenz

SUMMARYBy cytological diagnosis of chromosomal sex it has been shown, that about 80 per cent of all cases of gonadal dysgenesis are genetically male. In about 8 per cent of male individuals various defects of red-green sensitivity may be expected. Deuteranopia was observed in a hetero-gametic pseudo-female with testicular dysgenesis. Tests for colour vision should be made in all patients with the syndrome of testicular feminization. From such tests a decision may be expected between sex- linked recessive and autosomal dominant transmission with sex limitation.

2002 ◽  
Vol 116A (1) ◽  
pp. 37-43 ◽  
Author(s):  
C�dric Le Caignec ◽  
Sabine Baron ◽  
Ken McElreavey ◽  
Madeleine Joubert ◽  
Jean-Marie Rival ◽  
...  

2012 ◽  
Vol 18 (11) ◽  
Author(s):  
Cameron West ◽  
Swetha Narahari ◽  
Shawn Kwatra ◽  
Steven Feldman

1984 ◽  
Vol 105 (1) ◽  
pp. 47-51 ◽  
Author(s):  
Reuben D. Rohn ◽  
Mary S. Leffell ◽  
Paul Leadem ◽  
David Johnson ◽  
Thomas Rubio ◽  
...  

2020 ◽  
Vol 41 (02) ◽  
pp. 256-268 ◽  
Author(s):  
Kai-Feng Xu ◽  
Wenshuai Xu ◽  
Song Liu ◽  
Jane Yu ◽  
Xinlun Tian ◽  
...  

AbstractLymphangioleiomyomatosis (LAM) is a slow albeit progressive rare neoplastic disease featured with diffuse thin-walled cysts in lungs and angiomyolipomas in kidneys. LAM affects almost exclusively women and has one of the strongest gender predispositions of any extragenital human disease. Two forms of LAM present clinically, sporadic (S-LAM) and tuberous sclerosis complex-associated (TSC-LAM). TSC is an autosomal dominant genetic multisystems neoplastic disease. A high prevalence of LAM can be detected in adult female TSC patients. Tremendous progress has been made in our understanding and management of this rare disease. Both LAM and TSC are TSC2 or TSC1 mutated diseases that result in overactivation of the mechanistic target of rapamycin (mTOR) pathway. Sirolimus, an mTOR inhibitor, has been approved for LAM treatment in the United States and many other countries. Therapies targeting female sex hormones have shown preclinical efficacy in animal and cell culture-based experiments, but have not been properly investigated clinically. In this review, we summarize current recommendations in the diagnosis and treatment of LAM.


2001 ◽  
Vol 21 (10) ◽  
pp. 890-893 ◽  
Author(s):  
Gilles Morin ◽  
Jean Gekas ◽  
Philippe Naepels ◽  
Jean Gondry ◽  
Bernard Devauchelle ◽  
...  

1995 ◽  
Vol 233 (12) ◽  
pp. 805-806
Author(s):  
M.P. Snead ◽  
D.K. Newmann ◽  
A. Poulson ◽  
J.D. Scott ◽  
J. Rossier ◽  
...  

1999 ◽  
Vol 3 (3) ◽  
pp. 154-156 ◽  
Author(s):  
Sherri J. Bale

Background: A review of the recent progress made in mapping of the hereditary skin disease pseudoxanthoma elasticum is presented. Methods: Affected sib pair methods, parametric linkage analysis, and linkage heterogeneity tests are reviewed as applied to the effort to identify the location of the pseudoxanthoma elasticum gene. Results: Families segregating either autosomal dominant or autosomal recessive pseudoxanthoma elasticum mapped to chromosome 16p13.1. Conclusion: There is a gene for pseudoxanthoma elasticum on chromosome 16p. The underlying molecular defect remains to be elucidated.


2012 ◽  
Vol 97 (3) ◽  
pp. E423-E427 ◽  
Author(s):  
Peter J. Tebben ◽  
Dawn S. Milliner ◽  
Ronald L. Horst ◽  
Peter C. Harris ◽  
Ravinder J. Singh ◽  
...  

Author(s):  
B. Casey ◽  
B. F. Cuneo ◽  
C. Vitali ◽  
H. van Hecke ◽  
J. Barrish ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document